Aurobindo Pharma said its consolidated net profit increased 61 per cent year on year to Rs 919 crore in Q1FY25, aided by strong sales across markets, compared to Rs 571 crore in Q1FY24.
The Hyderabad-based drug maker’s revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement.
EBITDA before Forex and Other Income stood at Rs 1,620 crore with a margin at 21.4%.
Aurobindo Pharma reported a 13.3% increase in U.S. revenue year-on-year, reaching Rs 3,555 crore, which represents 47% of the company’s consolidated revenue. During the quarter, Aurobindo filed eight Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) and received final approval for ten ANDAs, including one specialty product.
As of June 30, 2024, the company has cumulatively filed 838 ANDAs with the FDA, receiving 668 final approvals and 26 tentative approvals. Aurobindo launched ten new products during the quarter, including one injectable.
Revenue from Europe rose by 7.9% to Rs 1,982 crore, accounting for 26.2% of consolidated revenue.
Meanwhile, revenue from growth markets’ formulations surged 49.2% to ₹709 crore, making up 9.4% of consolidated revenue. Its domestic sales stood at Rs 61 crore.
Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.”
